TY - JOUR
T1 - Clinical characteristics and outcomes for solitary fibrous tumor (SFT)
T2 - A single center experience
AU - DeVito, Nicholas
AU - Henderson, Evita
AU - Han, Gang
AU - Reed, Damon
AU - Bui, Marilyn M.
AU - Lavey, Robert
AU - Robinson, Lary
AU - Zager, Jonathan S.
AU - Gonzalez, Ricardo J.
AU - Sondak, Vernon K.
AU - Letson, G. Douglas
AU - Conley, Anthony
N1 - Publisher Copyright:
© 2015 DeVito et al.This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
PY - 2015/10/15
Y1 - 2015/10/15
N2 - Solitary fibrous tumor (SFT) is a mesenchymal neoplasm of fibrous origin. The 2013WHOclassification of soft tissue tumors defines malignant forms as hypercellular,mitotically active (>4 mitosis/10 high-power fields), with cytological atypia, tumor necrosis, and/or infiltrativemargins.With an IRB-approved protocol, we investigated patient records and clinicopathologic data fromour Sarcoma Database to describe the clinical characteristics of both benignand malignant SFT. All pathology specimens were reviewed by two pathologists. Descriptive statistics and univariate/multivariate survival analysis were performed. Patient records andSocial Security Death Index were used to evaluate vital status. Of 82 patients, 47 (57%) were women and 73 (89%) were Caucasian.Median age was 62 years (range, 20 to 89). Thirtytwo (39%) patients succumbed to the disease. Primary tumor site was lung/pleura in 28 (34%), abdomen/pelvis in 23 (28%), extremity in 13 (16%), and head/neck in 9 (11%)patients. Pathology was described as benign in 42 (51%) and malignant in 40 (49%) patients. Compared to benign SFT, malignant histology is associated with larger tumor size, highermitotic counts, metastatic disease at diagnosis, and greater use of chemotherapy and radiation therapy. Gender, age, and tumor site were not significantly different between benign andmalignant subtypes. By univariate analysis, only benign vs. malignant variant and complete resection positively impacted overall survival (P = 0.02 and P<0.0001, respectively). In themultivariable analysis of overall survival, receiving chemotherapy or not receiving surgery were two variables significantly associated with higher failure rate in overall survival: patientswith chemotherapy vs. no chemotherapy (P = 0.003, HR = 4.55, with 95%CI: 1.68-12.34) and patients without surgery vs. with surgery (P = 0.005, HR = 25.49, with 95%CI: 2.62-247.57). Clear survival differences exist between benign and malignant SFT. While surgery appears to be the best treatment option for benign and malignant SFT, better systemic therapiesare needed to improve outcomes of patients with metastatic, malignant SFT.
AB - Solitary fibrous tumor (SFT) is a mesenchymal neoplasm of fibrous origin. The 2013WHOclassification of soft tissue tumors defines malignant forms as hypercellular,mitotically active (>4 mitosis/10 high-power fields), with cytological atypia, tumor necrosis, and/or infiltrativemargins.With an IRB-approved protocol, we investigated patient records and clinicopathologic data fromour Sarcoma Database to describe the clinical characteristics of both benignand malignant SFT. All pathology specimens were reviewed by two pathologists. Descriptive statistics and univariate/multivariate survival analysis were performed. Patient records andSocial Security Death Index were used to evaluate vital status. Of 82 patients, 47 (57%) were women and 73 (89%) were Caucasian.Median age was 62 years (range, 20 to 89). Thirtytwo (39%) patients succumbed to the disease. Primary tumor site was lung/pleura in 28 (34%), abdomen/pelvis in 23 (28%), extremity in 13 (16%), and head/neck in 9 (11%)patients. Pathology was described as benign in 42 (51%) and malignant in 40 (49%) patients. Compared to benign SFT, malignant histology is associated with larger tumor size, highermitotic counts, metastatic disease at diagnosis, and greater use of chemotherapy and radiation therapy. Gender, age, and tumor site were not significantly different between benign andmalignant subtypes. By univariate analysis, only benign vs. malignant variant and complete resection positively impacted overall survival (P = 0.02 and P<0.0001, respectively). In themultivariable analysis of overall survival, receiving chemotherapy or not receiving surgery were two variables significantly associated with higher failure rate in overall survival: patientswith chemotherapy vs. no chemotherapy (P = 0.003, HR = 4.55, with 95%CI: 1.68-12.34) and patients without surgery vs. with surgery (P = 0.005, HR = 25.49, with 95%CI: 2.62-247.57). Clear survival differences exist between benign and malignant SFT. While surgery appears to be the best treatment option for benign and malignant SFT, better systemic therapiesare needed to improve outcomes of patients with metastatic, malignant SFT.
UR - http://www.scopus.com/inward/record.url?scp=84948991001&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84948991001&partnerID=8YFLogxK
U2 - 10.1371/journal.pone.0140362
DO - 10.1371/journal.pone.0140362
M3 - Article
C2 - 26469269
AN - SCOPUS:84948991001
SN - 1932-6203
VL - 10
JO - PloS one
JF - PloS one
IS - 10
M1 - e0140362
ER -